
Transparency and Reliability
Adjudication can be a tool to improve the confidence of trial data, although it is essential to have a clear and defined process. Historically,…
In light of JIA Awareness Month, its treatments, its stigma, and more, we spoke with Dr. Johnny Peppers, Executive Director of Drug Development for…
Over the past several months, participants in PRA Health Sciences’ Health Harmony COVID-19 Monitoring Program have had vital information about…
Adjudication can be a tool to improve the confidence of trial data, although it is essential to have a clear and defined process. Historically,…
Small and medium-sized enterprises (SMEs) are the backbone of Europe’s economy, representing 99% of all EU businesses. SMEs are often innovative…
Scientific advice is a regulatory process expected to, “facilitate timely access to safe and efficacious medicinal products to patients and users of…
The ebb and flow of a pharmaceutical or biotechnology company’s clinical development portfolio places an emphasis on ensuring that the resources…
In this white paper, you’ll learn more about how PRA is meeting the demands of the dynamic clinical research industry by supplying the next…
Innovative biotech products present a complex regulatory environment. For this reason, a formidable regulatory strategist is a critical member of the…
Glaucoma remains a chronic and visually debilitating disease that has vast public health implications, as well as pronounced effects on individual…
Selection of appropriate endpoints for rare disease clinical studies can be challenging but is critical to assessing the efficacy of new medicines.…
This white paper provides biotech companies an overview of the considerations for Chemistry, Manufacturing and Controls (CMC) in asset development.…
A single product candidate that provides clinical benefit across multiple indications and patient populations allows more conditions to be treated…